Collagen biomaterial for the treatment of myocardial infarction: an update on cardiac tissue engineering and myocardial regeneration

Drug Deliv Transl Res. 2019 Oct;9(5):920-934. doi: 10.1007/s13346-019-00627-0.

Abstract

Myocardial infarction (MI) remains one of the leading cause of mortality over the world. However, current treatments are more palliative than curative, which only stall the progression of the disease, but not reverse the disease. While stem cells or bioactive molecules therapy is promising, the limited survival and engraftment of bioactive agent due to a hostile environment is a bottleneck for MI treatment. In order to maximize the utility of stem cells and bioactive molecules for myocardial repair and regeneration, various types of biomaterials have been developed. Among them, collagen-based biomaterial is widely utilized for cardiac tissue engineering and regeneration due to its optimal physical and chemical properties. In this review, we summarize the properties of collagen-based biomaterial. Then, we discuss collagen-based biomaterial currently being applied to treat MI alone, or together with stem cells and/or bioactive molecules. Finally, the delivery system of collagen-based biomaterial will also be discussed.

Keywords: Biomaterials; Collagen; Delivery systems; Myocardial infarction; Stem cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Biocompatible Materials / administration & dosage*
  • Collagen / administration & dosage*
  • Heart / physiology
  • Humans
  • Myocardial Infarction / therapy*
  • Regeneration
  • Tissue Engineering

Substances

  • Biocompatible Materials
  • Collagen